Keros Therapeutics (KROS) Common Equity (2019 - 2025)

Keros Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $303.1 million for Q4 2025.

• Quarterly Common Equity fell 46.96% year-over-year to $303.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $303.1 million (down 46.96% YoY) and the FY2025 annual result came in at $303.1 million, down 46.96% from the prior year.
• Common Equity was $303.1 million for Q4 2025 at Keros Therapeutics, down from $703.6 million in the prior quarter.
• Across five years, Common Equity topped out at $728.9 million in Q1 2025 and bottomed at $211.2 million in Q2 2022.
• A 5-year average of $381.5 million and a median of $314.7 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity surged 1098.8% — and 2025, when it slumped 46.96%.
• Keros Therapeutics' Common Equity stood at $243.2 million in 2021, then gained by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then soared by 72.04% to $571.6 million in 2024, then plunged by 46.96% to $303.1 million in 2025.
• Business Quant data shows KROS's Common Equity at $303.1 million in Q4 2025, $703.6 million in Q3 2025, and $706.7 million in Q2 2025.